

37. **Golshan M**, Faghihi M, Marandi MM. Indoor women jobs and pulmonary risks in rural areas of Isfahan, Iran. *Respir Med* 2002;**96**:382–8.
38. **Kilabuko JH**, Matsuki H, Nakai S. Air quality and acute respiratory illness in biomass fuel using homes in Bagamoyo, Tanzania. *Int J Environ Res Public Health* 2007;**4**:39–44.
39. **Kiraz K**, Kart L, Demir R, *et al*. Chronic pulmonary disease in rural women exposed to biomass fumes. *Clin Invest Med* 2003;**26**:243–8.
40. **Liu S**, Zhou Y, Wang X, *et al*. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. *Thorax* 2007;**62**:889–97.
41. **Malik SK**. Exposure to domestic cooking fuels and chronic bronchitis. *Indian J Chest Dis Allied Sci* 1985;**27**:171–4.
42. **Mishra V**. Effect of indoor air pollution from biomass combustion on prevalence of asthma in the elderly. *Environ Health Perspect* 2003;**111**:71–8.
43. **Mishra V**. Indoor air pollution from biomass combustion and acute respiratory illness in preschool age children in Zimbabwe. *Int J Epidemiol* 2003;**32**:847–53.
44. **Mishra V**, Smith KR, Retherford RD. Effects of cooking smoke and environmental tobacco smoke on acute respiratory infections in young Indian children. *Popul Environ* 2005;**26**:375–96.
45. **Mishra V**, Retherford RD. Cooking smoke increases the risk of acute respiratory infection in children. *Natl Fam Health Surv Bull* 1997;**8**:1–4.
46. **Shrestha IL**, Shrestha SL. Indoor air pollution from biomass fuels and respiratory health of the exposed population in Nepalese households. *Int J Occup Environ Health* 2005;**11**:150–60.
47. **Uzun K**, Ozbay B, Ceylan E, *et al*. Prevalence of chronic bronchitis–asthma symptoms in biomass fuel exposed females. *Environ Health Prev Med* 2003;**8**:13–17.

Lung alert

Sildenafil does not improve 6 min walk distance in advanced idiopathic pulmonary fibrosis

It has been postulated that sildenafil, a phosphodiesterase-5 inhibitor and pulmonary artery vasodilator, may improve gas exchange in advanced idiopathic pulmonary fibrosis by preferentially increasing perfusion to well-ventilated areas of lung. This double-blind randomised placebo controlled study was designed to investigate the effect of sildenafil on 6 min walk distance (6MWD) in patients with advanced idiopathic pulmonary fibrosis (carbon monoxide diffusing capacity <35% predicted value).

A total of 180 patients from 14 centres were randomised to sildenafil or placebo with reassessment of 6MWD at 12 weeks. Both groups received open-label sildenafil from weeks 12 to 24. There was no significant difference in the primary outcome measure between the two groups (the proportion of patients with improved 6MWD of $\geq 20\%$). Small significant improvements were seen in secondary outcome measures at 12 weeks in the sildenafil treatment group including carbon monoxide diffusing capacity, oxygen partial pressure, St George's respiratory questionnaire total score and SF-36 general health score. These improvements were not observed in the placebo group who subsequently received sildenafil.

The study failed to meet the primary outcome measure, however the authors suggest that improvements in secondary outcomes were of clinical significance. They accept that assessment of the relation between treatment effect and severity of pulmonary vascular disease would have been valuable. The authors conclude that the therapeutic efficacy of sildenafil in advanced idiopathic pulmonary fibrosis remains uncertain and that further trials are necessary.

► **Zisman D**, Schwarz M, Anstrom K, *et al*; the Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Engl J Med* 2010;**363**:620–8.

M Lavender

Correspondence to M Lavender, Specialist Registrar, Salisbury District Hospital, Salisbury SP2 8BJ, UK; melanie.lavender@salisbury.nhs.uk

Provenance and peer review Not commissioned; not externally peer reviewed.

Published Online First 11 October 2010

Thorax 2011;**66**:239. doi:10.1136/thx.2010.145664